Cases in the management of metastatic colorectal cancer: Regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
JournalClinical Advances in Hematology and Oncology
Issue number8
StatePublished - Oct 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this